Loading clinical trials...

Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy | Clinical Trials | Clareo Health

COMPLETED

Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy

NCT04791852•Puerta de Hierro University Hospital

View on ClinicalTrials.gov

Summary

Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients over 18 and under 80 years old, HT \> 1 year ago

Exclusion Criteria

•Patients under 18 or over 80 years old
•Multiorgan transplant
•History of acute cellular rejection ≥ 1R or antibody mediated rejection in the previous 6 months
•Concomitant infection by CMV

Locations (1)

University Hospital Puerta de Hierro

Majadahonda, Madrid, Spain

Key Dates

Start Date

January 10, 2019

Primary Completion Date

January 31, 2021

Completion Date

April 15, 2021

Last Updated

September 16, 2021

Enrollment

ACTUAL participants

Conditions

Cardiac Allograft Vasculopathy

Interventions

Donor-derived Cell Free DNA

DIAGNOSTIC_TEST

Microvascular Cardiac Allograft Vasculopathy Trial

NCT05826444

Cardiac Allograft Vasculopathy

View study

WITHDRAWN

Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA

NCT05756088

Cardiac Allograft VasculopathyEndothelial Dysfunction+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 16, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy

Inclusion Criteria

Exclusion Criteria

Microvascular Cardiac Allograft Vasculopathy Trial

Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA

Heart Failure After Heart Transplantation Due to Chronic Rejection

Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation

Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant

Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation